StockNews.com Upgrades Regulus Therapeutics (NASDAQ:RGLS) to “Sell”

StockNews.com upgraded shares of Regulus Therapeutics (NASDAQ:RGLS) to a sell rating in a report released on Friday.

Other research analysts also recently issued reports about the company. Canaccord Genuity Group lifted their target price on Regulus Therapeutics from $11.00 to $28.00 and gave the stock a buy rating in a research note on Tuesday, June 25th. HC Wainwright reaffirmed a buy rating and set a $10.00 price objective on shares of Regulus Therapeutics in a research report on Friday, August 9th. Finally, Oppenheimer reiterated an outperform rating and issued a $7.00 price objective on shares of Regulus Therapeutics in a report on Wednesday, August 14th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of Moderate Buy and a consensus price target of $10.80.

Regulus Therapeutics Trading Up 3.4 %

Shares of RGLS opened at $1.51 on Friday. The company has a market cap of $98.86 million, a price-to-earnings ratio of -1.02 and a beta of 1.63. The company’s fifty day simple moving average is $1.67 and its 200 day simple moving average is $2.04. Regulus Therapeutics has a 1-year low of $1.08 and a 1-year high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.17). As a group, research analysts forecast that Regulus Therapeutics will post -0.8 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. NEA Management Company LLC bought a new stake in shares of Regulus Therapeutics in the first quarter valued at about $18,627,000. RA Capital Management L.P. acquired a new position in shares of Regulus Therapeutics during the 1st quarter worth approximately $18,000,000. CVI Holdings LLC bought a new position in shares of Regulus Therapeutics during the first quarter worth approximately $4,050,000. Vanguard Group Inc. raised its position in shares of Regulus Therapeutics by 158.4% in the first quarter. Vanguard Group Inc. now owns 740,215 shares of the biopharmaceutical company’s stock valued at $2,132,000 after buying an additional 453,784 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Regulus Therapeutics in the second quarter valued at approximately $352,000. Institutional investors own 92.38% of the company’s stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.